Previous studies have demonstrated that IGFBP3 negatively modulate the insulin secretion and insulin signaling pathway (D’Addio et al., 2022), exerting inhibitory effects on tumor cell proliferation and progression (Zhong et al., 2024; Kuhn et al., 2023). Here, INS is linked to neoplasm.